Treatment of male genital lichen sclerosus with heterologous type I collagen

Gkouvi, Aikaterini; Corbo, Andreas; Gregoriou, Stamatis

doi:10.1111/ced.14182

Cited by 4 publications

(18 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, less injectable products from horse collagen are available but recently discovered advantages deriving from its use [ 19 ] are driving the development of new equine collagen-based products. Among them, Nithya ® , Linerase ® (Euroresearch, Milan, Italy), Salvecoll-E ® (Nearmedic Italy S.r.l., Como, Italy), Biocollagen ® and ActivaBone ® (Bioteck Spa, Arcugnano, Italy) are commercially available and are mainly used for the treatment of diseases belonging to the integumental [ 163 , 164 ], urogenital [ 165 ] and gastrointestinal [ 160 ] apparatus. Its potential has also been recently explored for the treatment of periodontal tissues, with encouraging outcomes [ 166 , 167 ].…”

Section: Collagen-based Injectable Formulationsmentioning

confidence: 99%

“…Collagen-based formulations are mainly used for the treatment of several kind of diseases belonging mainly to the musculoskeletal (i.e., hip or knee osteoarthritis [ 112 , 131 , 133 , 140 , 142 , 144 , 182 ], sprained knee pain [ 143 ], injured cartilage [ 138 , 141 ], piriformis syndrome [ 136 ], ankle and hindfoot arthritis [ 103 ] or fusion [ 100 , 106 , 107 , 108 , 109 ], lumbar spinal fusion [ 99 ], myofascial pain syndrome [ 130 , 137 ], chronic pain [ 132 ], acute lumbar spine pain [ 134 ], partial-thickness rotator cuff tears [ 141 , 146 , 183 ], plantar fasciitis [ 184 ], calcific supraspinatus tendinitis [ 145 ], pain [ 130 , 132 , 134 , 137 ]), urogenital (i.e., urinary incontinence [ 122 , 124 , 125 , 185 , 186 , 187 , 188 , 189 ], neurogenic urinary incontinence [ 190 ], lichens sclerosus [ 165 ], intrinsic sphincter deficiency [ 191 , 192 , 193 ], post-prostatectomy incontinence [ 65 , 123 , 194 ,…”

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

“…Collagen injections have been revealed to be a minimally invasive and quite effective solution for specific urogenital system diseases such as stress urinary incontinence [ 122 , 124 , 125 , 185 , 186 , 187 , 188 , 189 ], neurogenic urinary incontinence [ 190 ], lichens sclerosus [ 165 ], intrinsic sphincter deficiency [ 191 , 192 , 193 ], post-prostatectomy incontinence [ 65 , 123 , 194 , 195 , 196 , 197 ], retrograde ejaculation [ 198 ] and ovarian function after premature ovarian failure [ 212 ].…”

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

“…Recently, collagen injections (Linerase ® ) have been proposed for the treatment of male genital lichen sclerosus and retrograde ejaculation. In the case of lichens sclerosus, it revealed to be safe and effective in 10 days and for up to 12 months [ 165 ]. Likewise, two injections of 6 mL of collagen (one per year) were revealed to be effective and complication free in cases of retrograde ejaculation [ 198 ].…”

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

“…The third most used collagen type Is equine derived collagen, whose use is very recent and thus limited compared to bovine and porcine derived injectable products. Indeed, it has been reported to be used (i.e., Linerase, Savecoll-E) only on 94 patients, with no adverse events and only one registered mild reaction (1.1%) [ 60 , 164 , 165 , 166 ]. Thus, although this percentage seems to be very low compared to other products, the limited number of executed procedures with equine collagen prevented the assessment of this collagen type as safer.…”

Section: Adverse Reactions To Collagen-based Injectable Implantsmentioning

confidence: 99%

See 4 more Smart Citations

An Update on the Clinical Efficacy and Safety of Collagen Injectables for Aesthetic and Regenerative Medicine Applications

Salvatore¹,

Natali

Brunetti³

et al. 2023

Polymers

View full text Add to dashboard Cite

Soft tissues diseases significantly affect patients quality of life and usually require targeted, costly and sometimes constant interventions. With the average lifetime increase, a proportional increase of age-related soft tissues diseases has been witnessed. Due to this, the last two decades have seen a tremendous demand for minimally invasive one-step resolutive procedures. Intensive scientific and industrial research has led to the recognition of injectable formulations as a new advantageous approach in the management of complex diseases that are challenging to treat with conventional strategies. Among them, collagen-based products are revealed to be one of the most promising among bioactive biomaterials-based formulations. Collagen is the most abundant structural protein of vertebrate connective tissues and, because of its structural and non-structural role, is one of the most widely used multifunctional biomaterials in the health-related sectors, including medical care and cosmetics. Indeed, collagen-based formulations are historically considered as the “gold standard” and from 1981 have been paving the way for the development of a new generation of fillers. A huge number of collagen-based injectable products have been approved worldwide for clinical use and have routinely been introduced in many clinical settings for both aesthetic and regenerative surgery. In this context, this review article aims to be an update on the clinical outcomes of approved collagen-based injectables for both aesthetic and regenerative medicine of the last 20 years with an in-depth focus on their safety and effectiveness for the treatment of diseases of the integumental, gastrointestinal, musculoskeletal, and urogenital apparatus.

show abstract

Section: Collagen-based Injectable Formulationsmentioning

confidence: 99%

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

Section: Clinical Efficacy Of Collagen-based Injectable Implantsmentioning

confidence: 99%

Section: Adverse Reactions To Collagen-based Injectable Implantsmentioning

confidence: 99%

See 3 more Smart Citations

An Update on the Clinical Efficacy and Safety of Collagen Injectables for Aesthetic and Regenerative Medicine Applications

Salvatore¹,

Natali

Brunetti³

et al. 2023

Polymers

View full text Add to dashboard Cite

show abstract

Treatment of Cutaneous Atrophy After Corticosteroid Injection, With Heterologous Type I Collagen

Gkouvi,

Corbo,

Gregoriou

2023

Dermatol Surg

View full text Add to dashboard Cite

S teroid-induced atrophy is a well-documented complication of intralesional steroid use with an estimated incidence varying from 1.5% to 40%. Cutaneous atrophy usually begins within 2 to 3 months of injection and regresses within 1 to 2 years. However, it has also been reported to persist beyond 5 years. 1 Treatment modalities that have been used to restore cutaneous atrophy include autologous fat injection, fat grafting, hyaluronic acid filler, pulsed dye laser, and intralesional bacteriostatic saline. We present 2 cases of steroid injection-induced atrophy treated with heterologous type I collagen (HTIC) (Linerase Collagen, Typeone Biomaterials Srl, Lecce, Italy).

show abstract

Tolerability and efficacy assessment of an oral collagen supplement for the improvement of biophysical and ultrasonographic parameters of skin in middle eastern consumers

Samadi

Movaffaghi

Kazemi

et al. 2023

J of Cosmetic Dermatology

View full text Add to dashboard Cite

Background Topical skin care products often do not reach the deeper layers of the skin, and oral hydrolyzed collagen is one of the newest and most popular systemic supplementations for skin rejuvenation. However, there are limited information in case of Middle Eastern consumers Objective The purpose of this study was to evaluate the tolerability and efficacy of an oral collagen supplement for improvement of skin elasticity, hydration, and roughness in Middle Eastern consumers. Methods and Materials It was a 12‐week, before‐after clinical study, conducted on 20 participants (18 women and 2 men) aged 44.15 ± 5.36 years with skin type III–IV. Skin elasticity parameters (R0, R2, R5, and R7), skin hydration and friction, as well as the thickness and echo density of the dermis, were measured after six and 12 weeks daily intake of the study product, as well as 4 weeks after stopping its use (week 16). Participants' satisfaction was assessed on the basis of their answers to the standard questionnaire, and tolerability of the product was assessed by monitoring the adverse effects. Results A significant improvement was detected in R2, R5, and skin friction at week 12 (p‐values 0.041, 0.012 and <0.01, respectively). At week 16, the values remained at an increased level, which indicates the persistence of the results. The increase of dermis density in week 16 was also significant (p‐value = 0.03). Moderate overall satisfaction was reported with the treatment, and a few gastrointestinal complications were reported. Conclusion The study demonstrated that oral collagen peptides could significantly improve the skin elasticity, roughness, and dermis echo density, and they also proved to be safe and well‐tolerated.

show abstract

Treatment of male genital lichen sclerosus with heterologous type I collagen

Abstract: Click https://www.wileyhealthlearning.com/ced.aspx for the corresponding questions to this CME article.

Cited by 4 publications

References 7 publications

An Update on the Clinical Efficacy and Safety of Collagen Injectables for Aesthetic and Regenerative Medicine Applications

An Update on the Clinical Efficacy and Safety of Collagen Injectables for Aesthetic and Regenerative Medicine Applications

Treatment of Cutaneous Atrophy After Corticosteroid Injection, With Heterologous Type I Collagen

Tolerability and efficacy assessment of an oral collagen supplement for the improvement of biophysical and ultrasonographic parameters of skin in middle eastern consumers

Contact Info

Product

Resources

About